Patients Pharmaceutical manufacturing Pharmaceutical products Prescription 
PM360
DECEMBER 20, 2023
Given China’s status as the world’s second most populous nation and an economic powerhouse, it represents both a monumental market opportunity and a dynamic arena of challenges for pharmaceutical products. Regulatory body – NMPA : all pharmaceutical products sold in the Chinese market need to be granted market authorization by NMPA.
pharmaphorum
OCTOBER 27, 2022
The Guidance will act as a non-binding and evolving resource for companies and provide additional clarification about communications with healthcare professionals (HCPs), healthcare organisations (HCOs), patient organisations (POs), and other stakeholders, including the general public.
Expert insights. Personalized for you.
105 
Let's personalize your content